Assay Development and Screening

Measuring cell-free, label-free drug binding kinetics to native integral membrane protein targets in the membrane.

Monday, February 5
4:00 PM - 4:30 PM
Location: 6C

Sponsored By 

Numerous valuable therapeutic targets are integral membrane proteins (IMP) such as GPCRs, ion channels, and transporters. However, IMPs are unstable when purified away from the membrane and cannot be isolated in their native state to evaluate the binding of drug candidates. This limitation forces lead development programs to introduce mutations and use detergent-based solubilization and reconstitution techniques to stabilize purified IMPs for ligand binding characterization. This expensive and time-consuming approach has limited success and introduces a significant risk to yield inaccurate kinetic binding information for lead selection. To address this challenge, we have developed a graphene bio-electronic sensor technology (GBEST) specifically designed to measure label-free kinetic binding of drug candidates to native IMP targets without removing them from the cell membrane.

A simple cell membrane preparation, expressing the target IMP, is used to cover the GBEST sensor surface with a flat membrane. A small voltage across the sensor creates a current that is highly sensitive to electrostatic changes in the immediate vicinity of the sensor surface. Thus, electrostatic changes caused by the binding of drugs to target IMPs in the membrane can be monitored in real time to generate label-free kinetic binding data in a cell-free system that includes all the natural components of the cell membrane.

The fluidity of the membrane is critical to support the IMP’s native conformation and function. We have successfully demonstrated that cell membranes deposited on the GBEST sensors remain fluid and show lateral movement of target IMPs in the plane of the membrane. Furthermore, direct demonstration of IMP fluidity confirms that its native conformation has not been altered by adsorption to the sensor surface.

We show that the GBEST biosensor detects real-time kinetic binding of small molecule and biotherapeutic drugs to IMPs, and we show that the KD value obtained with GBEST correlates well with the expected benchmark value.

We will present recent data sets and discuss the capabilities of the GBEST biosensor to enable lead characterization with native IMPs. The use of GBEST in lead discovery will enable lead characterization directly on native membranes to generate biologically relevant data for lead selection.

Jaime E. Arenas

Sr. Director, Science & Technology
Nanotech Biomachines

Dr. Arenas has more than 25 years of experience fueled by a passion to translate biomolecular interactions into breakthrough technological advances for drug discovery, diagnostics and life sciences. After developing a unique HTS paradigm for discovery of small molecules against undruggable antiviral RNA targets at Anadys Pharmaceuticals, he held leading roles at several companies focused on developing novel biosensor applications. He led development of applications for the launch of the array-based Flexchip SPR platform at Applied Biosystems. At BioScale, Dr Arenas invented the core biochemical approach for ultrasensitive biomarker assays in an acoustic MEMS platform. At TDK Headway technologies, he led development of a single molecule detection biosensor using tunneling magnetoresistance technology. Dr. Arenas is a Biologist, biochemist, and earned his PhD at the Albert Einstein College of Medicine in New York.


Send Email for Jaime Arenas


Measuring cell-free, label-free drug binding kinetics to native integral membrane protein targets in the membrane.

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Measuring cell-free, label-free drug binding kinetics to native integral membrane protein targets in the membrane.